Germline Susceptibility, Somatic Exposure Signatures, and Chromatin Accessibility as Drivers of Cancer-Type Divergence Among Carriers of the Same Predisposition Variant
This study demonstrates that the specific cancer types arising from inherited DNA repair gene mutations are driven by tissue-specific chromatin accessibility and somatic mutational signatures, revealing that the same genetic defect produces distinct biological consequences depending on the cellular context.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Every person carries a unique set of instructions in their cells, written in the language of DNA. Sometimes, a person inherits a specific error in these instructions, a mutation in a gene that normally helps prevent cancer. This is a known risk factor, a genetic hand dealt at birth that makes developing a tumor more likely. Yet, a puzzling mystery has long lingered in the medical world: why do two people with the exact same inherited error end up with completely different diseases? One might develop breast cancer, while another with the same mutation develops pancreatic cancer, or perhaps a tumor in the prostate. The mutation is identical, but the outcome is not. For years, scientists have wondered if the answer lies in the environment the cells live in, or perhaps in how the cells themselves are built.
To understand this, one must look at two things. First, cells are constantly bombarded by damage. Sunlight, smoke, and even the natural process of aging leave specific marks on DNA, like a fingerprint of the damage a tissue has endured over a lifetime. Second, DNA is not just a loose string; it is tightly wrapped around proteins, and only the parts that are unwrapped and open can be read by the cell's machinery. Different tissues have different parts of their DNA open or closed. A researcher named Rithvik Jangam set out to see if these two factors—the history of damage a tissue has suffered and how open its genetic pathways are—could explain why the same inherited mistake leads to different cancers.
Jangam turned to a massive public collection of cancer data known as The Cancer Genome Atlas. This database holds information on thousands of tumors from patients around the world. The challenge was that the public version of the data did not link specific patients to their inherited mutations, so the researcher could not simply look at the tumors of people who carried the bad gene. Instead, the study used a clever workaround. It looked for tumors where the same gene had been broken by a new, random mutation that happened inside the tumor itself. While this is not exactly the same as being born with the mutation, it asks a similar question: what happens to a tumor when this specific repair gene stops working?
The study began by building a list of genes where carriers were known to develop more than one type of cancer. This list included eleven genes, such as BRCA1 and BRCA2, which are famous for their link to breast and ovarian cancer, as well as others like ATM and PMS2. The first major discovery was that the tissues where these carriers developed cancer had very different histories of damage. For example, the lung tumors found in carriers of the ATM gene showed a strong fingerprint of smoking damage, while the skin tumors in the same group showed a clear signature of sun exposure. The bladder tumors showed a different pattern entirely, linked to a specific type of cellular enzyme activity. This confirmed that the tissues where these cancers appear have lived through very different kinds of DNA damage, suggesting that the local environment plays a huge role in deciding where a genetic risk turns into a disease.
The second part of the investigation focused on the "openness" of the DNA. The researcher checked whether the biological pathways that these genes belong to were more accessible in the tissues where cancer actually occurred. The results were striking for one gene in particular: BRCA2. In the tissues where BRCA2 carriers typically get cancer, the DNA regions responsible for a specific repair process called homologous recombination were significantly more open and accessible. This was true in both normal tissue samples and in the tumors themselves. In contrast, this openness was not seen in tissues where BRCA2 carriers rarely develop cancer. This suggests that the tissues most vulnerable to this mutation are the ones that rely most heavily on this specific repair pathway, making them more dependent on a gene that is already broken.
The most compelling evidence came from looking for a specific "scar" left behind when the repair system fails. When the BRCA1 or BRCA2 genes are broken, the cell loses its ability to fix double-strand breaks in DNA accurately. Instead, it uses a distinct repair method that leaves a flat pattern of mutations known as SBS3. The study found that in breast tumors where the BRCA2 gene was broken, this scar was everywhere, making up more than half of the mutations in those tumors. However, in tumors from other parts of the body, such as the lung or colon, even when the BRCA2 gene was broken, this scar was almost entirely absent. The effect was not uniform; it depended entirely on the tissue. The same broken gene left a massive mark in the breast and prostate, but left almost no trace in the lung or bladder.
This finding challenges the idea that a broken gene acts the same way everywhere in the body. The study showed that the impact of losing a repair gene is not just about the gene itself, but about the tissue it lives in. The tissues where carriers get cancer are the ones that are most open to the repair pathway and the ones that show the strongest signs of repair failure when the gene is lost. For the other genes studied, the picture was less clear, with some showing no such pattern, suggesting that different genes influence cancer risk through different mechanisms. The research also highlighted that simply finding a broken gene in a tumor might not be enough to predict how the cancer will behave or how it should be treated, because the tissue context changes everything.
The study concludes that the story of inherited cancer is not written by the gene alone. It is a collaboration between the inherited mistake and the specific biology of the tissue where the cancer starts. The history of damage a tissue has endured and how open its genetic pathways are seem to decide whether a shared genetic risk becomes a breast tumor, a prostate tumor, or something else entirely. While the research relied on public data and used tumor mutations as a stand-in for inherited ones, the patterns found are strong and consistent. The next step for scientists is to confirm these findings by looking directly at the tumors of people who were born with these mutations, but the current work offers a clear new perspective: the body is not a uniform landscape, and the same genetic error can have very different consequences depending on the soil in which it grows.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.